SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AFT Pharmaceuticals enters exclusive development, license and supply agreement with Mikasaseiyaku

AFT grants Mikasaseiyaku an exclusive licence to seek marketing authorisation and commercialise Maxigesic IV in Japan.

AFT.NZ

Related stories